Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has closed the ...

The newly formed firm and group are announcing their intention to raise initial bridge financing through offerings under the U.S. SEC's Regulation D and a Hong Kong Stock Exchange (HKEx) debt ...

Nebius Group (NBIS) said it has closed a private offering of convertible senior notes, raising around $4.3B in gross proceeds as the company looks to fund data center build-outs and expand its ...

Jefferies, Evercore ISI, Citigroup and Guggenheim Securities are acting as joint-book running managers for the Convertible Notes Offering and Equity Offering. Wedbush PacGrow is acting as co-manager ...

Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and ...

(NYSE: WT) ("WisdomTree"), a global financial innovator, today announced its intention to offer, subject to market conditions ...

Liberty Energy (LBRT) has just completed a US$475 million offering of zero coupon, senior unsecured convertible notes due March 1, 2032, a financing move that puts the company’s capital structure in ...

PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (GH), a leading precision oncology company, today announced the pricing of its upsized offering of $350.0 million aggregate principal amount ...

Shares of Zenas BioPharma fell after the clinical-stage biopharmaceutical company said it commenced an underwritten public offering of notes and stock. The stock slipped 9.8%, to $20, after-hours ...

NEW YORK, Jan. 26, 2026 /PRNewswire/ -- WhiteFiber, Inc. (Nasdaq: WYFI) ("WhiteFiber" or the "Company"), a provider purpose-built for artificial intelligence ("AI ...

“We are extremely pleased with the outstanding response to the Convertible Note Offering from high quality institutional investors in the United States, which is a tremendous endorsement of Caledonia ...

Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in ...